NYSE
BLCO

Bausch + Lomb Corp

Medical Instruments & Supplies
Healthcare

Prices are adjusted according to historical splits.

Bausch + Lomb Corp Stock Price

Vitals

Today's Low:
$17.56
Today's High:
$17.915
Open Price:
$17.64
52W Low:
$12.2
52W High:
$19.96
Prev. Close:
$17.66
Volume:
411290

Company Statistics

Market Cap.:
$6.46 billion
Book Value:
19.942
Revenue TTM:
$3.81 billion
Operating Margin TTM:
4.49%
Gross Profit TTM:
$2.25 billion
Profit Margin:
-2.73%
Return on Assets TTM:
0.97%
Return on Equity TTM:
-1.35%

Company Profile

Bausch + Lomb Corp had its IPO on 2022-05-06 under the ticker symbol BLCO.

The company operates in the Healthcare sector and Medical Instruments & Supplies industry. Bausch + Lomb Corp has a staff strength of 12,900 employees.

Stock update

Shares of Bausch + Lomb Corp opened at $17.64 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $17.56 - $17.92, and closed at $17.71.

This is a +0.28% increase from the previous day's closing price.

A total volume of 411,290 shares were traded at the close of the day’s session.

In the last one week, shares of Bausch + Lomb Corp have slipped by -1.34%.

Bausch + Lomb Corp's Key Ratios

Bausch + Lomb Corp has a market cap of $6.46 billion, indicating a price to book ratio of 0.8057 and a price to sales ratio of 1.4156.

In the last 12-months Bausch + Lomb Corp’s revenue was $3.81 billion with a gross profit of $2.25 billion and an EBITDA of $546 million. The EBITDA ratio measures Bausch + Lomb Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Bausch + Lomb Corp’s operating margin was 4.49% while its return on assets stood at 0.97% with a return of equity of -1.35%.

In Q1, Bausch + Lomb Corp’s quarterly earnings growth was a negative -88.6% while revenue growth was a positive 4.7%.

Bausch + Lomb Corp’s PE and PEG Ratio

Forward PE
23.31
Trailing PE
0
PEG
2.5725

Its diluted EPS in the last 12-months stands at $-0.3 per share while it has a forward price to earnings multiple of 23.31 and a PEG multiple of 2.5725. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bausch + Lomb Corp’s profitability.

Bausch + Lomb Corp stock is trading at a EV to sales ratio of 2.0019 and a EV to EBITDA ratio of 11.2064. Its price to sales ratio in the trailing 12-months stood at 1.4156.

Bausch + Lomb Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$11.17 billion
Total Liabilities
$1.25 billion
Operating Cash Flow
$-64000000.00
Capital Expenditure
$37 million
Dividend Payout Ratio
0%

Bausch + Lomb Corp ended 2024 with $11.17 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $11.17 billion while shareholder equity stood at $6.98 billion.

Bausch + Lomb Corp ended 2024 with $14.00 million in deferred long-term liabilities, $1.25 billion in other current liabilities, in common stock, $-84000000.00 in retained earnings and $4.52 billion in goodwill. Its cash balance stood at $346.00 million and cash and short-term investments were $346.00 million. The company’s total short-term debt was $25,000,000 while long-term debt stood at $2.51 billion.

Bausch + Lomb Corp’s total current assets stands at $2.18 billion while long-term investments were $0 and short-term investments were $0. Its net receivables were $714.00 million compared to accounts payable of $389.00 million and inventory worth $697.00 million.

In 2024, Bausch + Lomb Corp's operating cash flow was $-64000000.00 while its capital expenditure stood at $37 million.

Comparatively, Bausch + Lomb Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$17.71
52-Week High
$19.96
52-Week Low
$12.2
Analyst Target Price
$28.38

Bausch + Lomb Corp stock is currently trading at $17.71 per share. It touched a 52-week high of $19.96 and a 52-week low of $19.96. Analysts tracking the stock have a 12-month average target price of $28.38.

Its 50-day moving average was $19.09 and 200-day moving average was $17.61 The short ratio stood at 17.96 indicating a short percent outstanding of 0%.

Around 8873.5% of the company’s stock are held by insiders while 1305.2% are held by institutions.

Frequently Asked Questions About Bausch + Lomb Corp

The stock symbol (also called stock or share ticker) of Bausch + Lomb Corp is BLCO

The IPO of Bausch + Lomb Corp took place on 2022-05-06

Similar Industry Stocks (Medical Instruments & Supplies)

Last Price
Chg
Chg%
$216.4
-6.9
-3.09%
$0.02
-0
-0.9%
$347.84
-3.75
-1.07%
$2.5
0
0%
$67.48
3.21
+4.99%
$28.64
-1.81
-5.95%
$33
-1.58
-4.57%
$7.32
-0.08
-1.08%
$0.78
0
0%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Address

520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4